CoreLogic
CoreLogic Raises $300M Series D to Transform Biotech
CoreLogic Raises $300M Series D in Latest Funding Round
CoreLogic has successfully closed a $300M Series D funding round, marking a significant milestone in the company's growth trajectory. The round was led by NEA, with participation from Bessemer Venture Partners.
Company Overview
Founded in 2025 and headquartered in Washington, DC, CoreLogic has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models
With a current valuation of $2B, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $300M Series D
- Valuation: $2B
- Lead Investor: NEA
Future Outlook
As CoreLogic moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free